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Percutaneous Coronary Interventions
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MaBleeding avoidance strategies for percutaneous coronary interventions continue to evolve with the availability of newer
antiplatelet and anticoagulation therapies. Advances in interventional practices have altered the balance between
ischemic and bleeding complications. With the availability of rapidly-acting platelet adenosine diphosphate–receptor
antagonists, the need for routine glycoprotein IIb/IIIa inhibitors has diminished. Recent meta-analyses and trials have
advanced our knowledge of vascular access and different anticoagulation regimens. Vascular closure devices have
long been used for early ambulation; however, more recent results demonstrating lower bleeding complications
from observational registries are encouraging. This review synthesizes this information, taking into account changes
in the landscape of interventional practice with respect to current bleeding avoidance strategies. (J Am Coll Cardiol
2015;65:2225–38) © 2015 by the American College of Cardiology Foundation.B leeding and vascular complications in pa-tients undergoing percutaneous coronaryinterventions (PCIs) are associated with
signiﬁcant costs, prolonged hospital stays, and in-
creased short- and long-term morbidity and mortality
(1–5). The risk of bleeding is modiﬁable, and im-
proving bleeding and vascular complication rates pro-
vides an opportunity to improve the health care and
safety of PCI. In that regard, the Centers for Medicare
and Medicaid Services (6) have identiﬁed bleeding
and hematoma following cardiovascular procedures
as quality indicators (7).
Marso et al. (8) used the term “bleeding avoid-
ance strategies” to highlight the importance of
bivalirudin and vascular closure devices (VCDs) in
reducing bleeding, using data on more than 1.5
million patients undergoing PCI at hospitals
participating in the National Cardiovascular Data
Registry (NCDR) (8). In high-risk patients, the use of
both bivalirudin and VCD was associated with
signiﬁcantly lower bleeding rates. Since the publi-
cation of this study, pharmacotherapy andm the Division of Cardiovascular Diseases, Department of Internal Medici
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factors that can further mitigate bleeding risk in
patients undergoing PCI.
With this backdrop, this review will report recent
advances associated with meaningful reduction in
bleeding complications following PCI. It will also re-
view the current data on the status of bivalirudin and
VCD. Last, this review will provide the reader with a
practical strategy to help individualize a patient’s
bleeding risk and deploy interventions to reduce
bleeding in high-risk patients.
DEFINITION OF BLEEDING
Bleeding complications have been identiﬁed as a
crucial endpoint to test the safety and efﬁcacy of new
antithrombotic drugs, cardiac devices, or PCI.
Reduction in bleeding events is associated with
improved survival, and prevention of major bleeding
may represent an important step in improving
outcomes by balancing the safety and efﬁcacy of
pharmacotherapy and devices used during PCI (9).ne, Mayo Clinic, Rochester, Minnesota. Dr. Singh has
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2226Lack of unanimity in deﬁning bleeding has
led to variation in the incidence of bleeding
across institutions performing PCI (1). The
deﬁnition of bleeding continues to evolve,
and 4 such deﬁnitions are highlighted in
Figure 1. One deﬁnition, coined by the
Bleeding Academic Research Consortium
(BARC), classiﬁes bleeding into 5 clinically-
meaningful categories (10). This deﬁnition
not only captures the cause (procedural or
nonprocedural) of bleeding, but also reﬂects
on the severity, site, and prognostic impli-
cations (6). BARC also gives due consider-
ation to coronary artery bypass graft (CABG)–
related bleeding, as up to 12% of patientspresenting with acute coronary syndromes (ACS) may
undergo CABG during index hospitalization. The key
determinants of CABG-related bleeding include:
duration (24 h for chest tube and 48 h for intracranial
bleed and transfusions); site (intracranial); and need
for reoperation. The second deﬁnition proposed by
the NCDR is being used to calculate the bleeding risk
score (11). This deﬁnition encompasses a broader
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(Thrombolysis In Myocardial Infarction) and GUSTO
(Global Utilization of Streptokinase and Tissue Plas-
minogen Activator for Occluded Coronary Arteries)
trials (12,13). Figure 1 highlights the signiﬁcant het-
erogeneity in deﬁnitions of bleeding. Such variations
make the adjudication of endpoints, intertrial com-
parisons, and care process improvements difﬁcult, if
not impossible.
There are still some unresolved issues. First, cli-
nicians still must use the NCDR deﬁnition to calcu-
late the bleeding risk from PCI, and BARC or other
deﬁnitions need to be utilized to judge severity.
Second, the NCDR deﬁnition is for bleeding within
72 h of PCI and is mainly geared to capture PCI-
related complications, whereas the BARC deﬁnition
may need to be used to calculate the short- and
long-term bleeding risk. Third, at present, access
and nonaccess bleeding are not well-differentiated.
Nonaccess-site bleeds are more common in patients
who present with ACS, have an adverse prognosticMinimal: Overt hemorrhage
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FIGURE 2 Temporal Trends in Major Vascular Complications
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Review of 4 major studies showing decline in vascular compli-
cations over time. The differences in the incidence among studies
likely reﬂect use of different deﬁnitions of vascular complica-
tions. Reprinted with permission from Dauerman et al. (22).
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2227connotation, and do not share a similar temporal
decline as access-site bleeds, and their prevalence,
predictors, and prognostic importance need to be
captured separately (5,14–16).
INCIDENCE AND PREDICTORS OF
BLEEDING FOLLOWING PCI
INCIDENCE OF BLEEDING COMPLICATIONS. Varying
estimates from several registries’ data reﬂect hetero-
geneity in deﬁning signiﬁcant bleeding following PCI.
Many centers include hematoma in their bleeding
deﬁnition, leading to higher bleeding estimates, as
compared with more stringent deﬁnitions that rely on
a signiﬁcant hemoglobin drop of $3 g/dl with or
without other major complications (e.g., intraocular
or cerebral bleed). For example, data from the Mayo
Clinic included hematomas in their deﬁnition of
bleeding and reported higher rates of major vascular
complications (3.5% in the contemporary era between
2000 and 2005), as compared with 2.4% in the
NCDR, which included blood transfusion/prolonged
hospital stay and/or hemoglobin drop $3 g/dl and
access or nonaccess site bleeding (14,17). There is an
urgent need to adopt a universal deﬁnition for
bleeding that will facilitate studying temporal trends
and interinstitutional comparisons and that will unify
efforts to improve them.
PREDICTORS OF BLEEDING. Doyle et al. (17) found
female sex, older age, renal impairment, larger sheath
size, higher activated clotting time (ACT), use of
glycoprotein (GP) IIb/IIIa inhibitors, VCD use, and
longer procedure time to be predictors of higher
bleeding among patients undergoing PCI through the
femoral route. Two models from the NCDR identiﬁed
heart failure, peripheral vascular disease, and pre-
sentation with ACS as additional variables predicting
bleeding (11,18). Identifying predictors associated
with higher bleeding rates should prompt health care
providers to seek strategies and interventions to
lower the risk.
TEMPORAL BLEEDING TRENDS. Risk estimates for
bleeding differed among studies, as they used
different deﬁnitions of bleeding, making interstudy
comparisons difﬁcult. Regardless of the deﬁnition
used, all studies have demonstrated a remarkable
decline in access-site bleeding following PCI (17,19–22)
(Figure 2). The likely reasons for the decline
include, among others: increase in the use of radial
access; smaller sheath size for femoral access;
bivalirudin use; and judicious utilization of GP IIb/
IIIa inhibitors. Nonaccess-site bleeds have not
shared similar declines and continue to dominate
in patients with ACS (14).BLEEDING RISK ESTIMATION. The available risk
models are sparsely used to predict bleeding and to
stratify patients into different risk categories. Indi-
vidualizing a patient’s bleeding risk may help pro-
viders to tailor access and antithrombotic therapy,
choose the duration and severity of anticoagulation,
and obviate the need for GP IIb/IIIa inhibitors (23).
Due to signiﬁcant overlap in variables predicting
bleeding and other major adverse cardiovascular
endpoints, bleeding risk models may also help pro-
viders predict mortality and other ischemic endpoints
(24–26).
Two contemporary bleeding risk models are avail-
able. The ﬁrst model is derived from 3 trials of ACS
and comprises 7 easily-obtainable variables (serum
creatinine, age, sex, presentation, white blood cell
count, cigarette smoking, and randomized treat-
ment). TIMI (Thrombolysis In Myocardial Infarction)
major bleeding rates increased by bleeding risk score
groups, from 0.4% for those in the lowest-risk group
to 5.8% for those in the highest-risk group (Figure 3)
(27). The second model is derived from the NCDR
database, is contemporary, and can be used even in
patients undergoing elective PCI (Figure 4) (11).
A patient with a higher bleeding risk can be easily
identiﬁed with these models (e.g., elderly women
presenting with ACS), allowing bleeding avoidance
strategies to be preferentially targeted to these pa-
tients (28).
PROGNOSTIC IMPLICATIONS OF BLEEDING
Bleeding following PCI is associated with an
increased risk of adverse cardiovascular outcomes
(17,29–33). Higher risks for mortality, MI, and stent
FIGURE 3 Bleeding Risk Model
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This simple, easy-to-use model is derived from 3 trials of acute coronary syndrome. For a patient who has a creatinine of 1.3 mg/dl, is 72 years
of age, is female, has a white cell count of 11  109/l, has non–ST-segment elevation myocardial infarction (NSTEMI) without raised bio-
markers, and is a nonsmoker, her risk score would be: 4 þ 9 þ 4 þ 5 þ 1 þ 0 þ 0 ¼ 19, signifying a 2.7% chance of a non-CABG–related
TIMI major bleed within 30 days. If the patient is treated with bivalirudin alone rather than a heparin plus a glycoprotein IIb/IIIa inhibitor,
the total score should be reduced by 6 to 13 points, indicating a 1.4% chance of a non-CABG–related TIMI major bleed within 30 days.
Reprinted with permission from Mehran et al. (27). PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial
infarction; other abbreviations as in Figure 1.
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2228thrombosis are noted in patients with bleeding, and
bleeding avoidance strategies are associated with
improvements in survival (8). The increased risk from
bleeding is not limited to the index hospital admis-
sion (5); long-term hazard is also noted (6). The un-
derlying mechanisms may include: prothrombotic
state; abrupt discontinuation of antiplatelet and
anticoagulant therapies; increasing the risk of stent
thrombosis; greater prevalence of comorbidities in
patients who bleed; anemia; and the effect of blood
transfusions to treat bleeding (10,34). Stored blood
used for transfusion has: low 2,3-diphosphoglyceric
acid activity, thereby increasing the oxygen afﬁnity
of hemoglobin and decreasing tissue oxygen de-
livery (35); decreased red blood cell deformability,
leading to increases in osmotic fragility, aggreg-
ability, and intracellular viscosity (36); disrupted
nitric oxide transport (37); prothrombotic effects; andtransfusion-related immunomodulation (38). The as-
sociation of blood transfusion with poor prognosis
should warrant caution toward routine blood trans-
fusions in anemic, but stable patients (39,40), but
should not deter clinicians from providing this ther-
apy if severe anemia is associated with signs of
ischemia (34).
ADVANCES IN PHARMACOTHERAPY
The temporal decline in bleeding complications
following PCI has followed an evolutionary change
in the type and intensity of anticoagulation and
antithrombotic therapy. Very high bleeding compli-
cations were observed during the 1990s in trials that
mandated the use of GP IIb/IIIa inhibitors con-
comitant to intensive heparin therapy (41–43). With
the use of less intense anticoagulation and with the
FIGURE 4 NCDR Bleeding Risk Model
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This contemporary model is derived from the National Cardiovascular Data Registry (NCDR), is integer-based, and is parsimonious. Reprinted
with permission from Rao et al. (11). BMI ¼ body mass index; Hb ¼ hemoglobin; other abbreviations as in Figure 3.
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2229advent of dual antiplatelet therapy in the late
1990s, bleeding complications were less commonly
observed.
Dosing errors still occur and are prevalent in
vulnerable populations at high risk for bleeding. In an
observational analysis of 30,136 patients from the
CRUSADE (Can Rapid Risk Stratiﬁcation of Unstable
Angina Patients Suppress Adverse Outcomes With
Early Implementation of the American College of
Cardiology/American Heart Association Guidelines)
trial, 42% of patients admitted with non–ST-segment
elevation myocardial infarction (STEMI) were ad-
ministered excessive dosing of unfractionated or low-
molecular-weight heparin and GP IIb/IIIa inhibitors
(44), which was associated with higher bleeding risk
and poor outcomes. This underscores the need for
national quality improvement initiatives to reduce
dosing errors, thereby yielding improvement in
outcomes.HEPARIN AND ACT. Since the introduction of PCI,
intravenous unfractionated heparin has been the
cornerstone of antithrombotic therapy. Despite its
universal acceptance, there is still controversy
regarding the optimal dose and ACT that reﬂects
equipoise between bleeding and ischemic complica-
tions. In the ESPRIT (Enhanced Suppression of the
Platelet IIb/IIIa Receptor with Integrilin Therapy)
trial, ischemic endpoints in patients undergoing
contemporary PCI with stent placement did not in-
crease with lower ACT levels, at least to a level of
200 s; however, a modest correlation with bleeding
was observed at higher ACT levels (45). The current
American College of Cardiology/American Heart As-
sociation PCI guidelines agree that current dosing of
heparin is on the basis of empiricism and experience
from randomized trials, and the utility of measured
ACT levels in current practice remains uncertain (46).
ACT between 200 and 250 s with GP IIb/IIIa inhibitors,
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2230and between 250 and 300 s without, remains standard
practice with unfractionated heparin during PCI,
and operators are encouraged to keep the ACT on
the lower end of the recommended range to lower
bleeding complications.
DUAL ANTIPLATELET THERAPY
The PLATO (Platelet inhibition and Patient Outcomes)
trial demonstrated that ticagrelor (an orally-active
agent that binds reversibly to P2Y12), as compared
with clopidogrel (irreversible blockade of P2Y12,
delayed onset, needs cytochrome P450), was associ-
ated with a 16% relative risk reduction with regard
to a composite of cardiovascular death, myocardial
infarction, and stroke (47). Compared with the CURE
(Clopidogrel in Unstable Angina to Prevent Recurrent
Events) and TRITON-TIMI 38 (Therapeutic Outcomes
by Optimizing Platelet Inhibition with Prasugrel–
Thrombolysis In Myocardial Infarction 38) trials
(48–50), not only did PLATO demonstrate signiﬁcant
mortality (death from any cause) reduction (4.5%
with ticagrelor and 5.9% with clopidogrel), but
the bleeding risk did not increase (major bleeding
11.6% vs. 11.2% with clopidogrel) (Figure 5). However,
non-CABG bleeding was signiﬁcantly higher in pa-
tients treated with ticagrelor. The newer antiplatelet
therapies provide patients with early, reversible,
and predictable platelet inhibition, with reduction inison of Dual Antiplatelet Trials
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bolysis in Myocardial Infarction 38) included patients who had acute corona
omig (106). CHAMPION ¼ Cangrelor versus Standard Therapy to Achieve Op
MI ¼ myocardial infarction; RR ¼ risk ratio.ischemic endpoints and, importantly, without in-
creased bleeding complications. Similar results were
recently reported with intravenous infusion of can-
grelor, an intravenous, fast-acting, reversible, and
direct-acting P2Y12 inhibitor. Its antiplatelet effects
are immediate and can be maintained with contin-
uous infusion. The plasma half-life of cangrelor is
approximately 3 to 5 min, and platelet function is
restored within 1 h after cessation of the infusion. The
use of cangrelor in patients undergoing PCI was
studied in 2 phase 3 trials, the CHAMPION (Cangrelor
versus Standard Therapy to Achieve Optimal Man-
agement of Platelet Inhibition) PCI and CHAMPION
PLATFORM studies (51). Cangrelor was not associated
with a signiﬁcant reduction in the primary efﬁcacy
endpoint in either trial, but was associated with
reductions in secondary endpoints, including the rate
of stent thrombosis, with no excess severe bleeding.
The recent CHAMPION PHOENIX trial, comparing
cangrelor with clopidogrel, demonstrated the supe-
riority of cangrelor, both for reducing ischemic events
and for not increasing bleeding complications
following elective and urgent PCIs (52). Advances in
dual antiplatelet therapy have led to early, predict-
able, and reversible platelet inhibition, obviating the
need for routine GP IIb/IIIa inhibition, and thereby
reducing bleeding complications.
BIVALIRUDIN AND PCI. Bivalirudin is an intra-
venous direct thrombin inhibitor that is used as an5.9
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2231alternative to heparin in patients undergoing PCI.
Trials that compared bivalirudin with heparin found
that net adverse cardiovascular events, which
included ischemic and bleeding endpoints, favored
bivalirudin, with superior or noninferior results
(9,53–55). The beneﬁt was driven primarily by lower
bleeding complications. There are several limitations
of the previously-published trials that compared
heparin versus bivalirudin monotherapy for PCI.
First, the intensity of antiplatelet and anticoagulation
therapies was disparate and weighted heavily toward
the heparin monotherapy arm (56). This made inter-
pretation of the primary endpoint challenging, with 2
treatment arms expected to have completely opposite
effects on the incidence of thrombotic and bleeding
complications. For example, in patients treated with
heparin monotherapy, differential and routine use of
GP IIb/IIIa agents was associated with a higher risk of
bleeding complications. Second, even in more recent
trials, such as the EUROMAX (European Ambulance
Acute Coronary Syndrome Angiography) trial, an
international, randomized, open-label study that
demonstrated that bivalirudin, initiated during
transport for primary PCI in patients with STEMI, was
superior to heparin, the dose of heparin (100 IU/kg)
and concomitant optional use of GP IIb/IIIa inhibitors
(69.1%) was high, leading to increased bleeding
complications in the heparin arm (57). Third, ischemic
events, speciﬁcally acute myocardial infarction or
stent thrombosis (especially within the ﬁrst 24 h),
were more frequently noted in patients treated with
bivalirudin (58). Despite the consistent, but nonsig-
niﬁcant increase in ischemic events, the concomitant
reduction in bleeding events in the bivalirudin-
treated patients favored its use as monotherapy.
Fourth, upstream use of dual antiplatelet therapy,
especially with newer and faster-acting agents, has
led to reductions in the routine use of GP IIb/IIIa
agents, currently at 28% from 41% (14). This has led to
newer trials comparing heparin versus bivalirudin
monotherapies, with optional and lower use of GP IIb/
IIIa inhibitors. In HEAT-PPCI (How Effective are
Antithrombotic Therapies in Primary Percutaneous
Coronary Intervention), among 1,829 patients who
underwent emergent coronary angiography at a sin-
gle center, GP IIb/IIIa inhibitor usage was low (13% to
15%) and was equal in the heparin and bivalirudin arms.
The primary efﬁcacy outcome at 28 days (all-cause
mortality, myocardial infarction, cerebrovascular ac-
cidents, unplanned target lesion revascularization)
favored heparin (5.7% compared with 8.7% in the
bivalirudin group) (59). The primary safety endpoint
of major bleeding was similar in the 2 groups. It
should be noted that the median ACT value in theHEAT-PPCI trial was lower in the heparin arm (206 s)
compared with the bivalirudin arm (246 s) and with
other primary PCI trials. In the meta-analyses (58),
additional heparin and prolonged duration of bival-
irudin did not improve ischemic outcomes; however,
in the Swedish Coronary Angiography and Angio-
plasty Registry, an additional dose of heparin led to
improved rates of myocardial infarction (60).
BRIGHT (Bivalirudin in Acute Myocardial Infarc-
tion vs Heparin and GPI Plus Heparin Trial), studied
bivalirudin in patients undergoing PCI. The trial was
performed in 82 centers in China and randomized
2,194 patients into: bivalirudin and provisional GP
IIb/IIIa inhibitors (n ¼ 735); heparin and provisional
GP IIb/IIIa inhibitors (n ¼ 729); or heparin and routine
GP IIb/IIIa inhibitors (n ¼ 730) (61). The net adverse
clinical endpoint was lower in the bivalirudin group
(65 events, 8.8%) than with either heparin and pro-
visional GP IIb/IIIa inhibitors (96 events, 13.2%) or
heparin and routine GP IIb/IIIa inhibitors (124 events,
17.0%). The differences between the groups were
almost entirely driven by the differences in the any-
bleeding category. There were no differences in
ischemic events, including stent thrombosis. In the
MATRIX (Minimizing Adverse Haemorrhagic Events
by TRansradial Access Site and Systemic Imple-
mentation of angioX) trial of 7,200 ACS patients un-
dergoing PCI randomized to bivalirudin or
unfractionated heparin, Valgimigli (62) did not report
signiﬁcant improvement in risk of cardiac events or
cardiac events plus major bleeding after taking
bivalirudin, as compared with standard care. How-
ever, bivalirudin was shown to signiﬁcantly lower the
risk of bleeding complications, especially near the
catheter insertion site, which occurred in 1.7% with
bivalirudin versus 2.3% in the standard-care group.
Additionally, the bivalirudin group had a signiﬁcantly
lower rate of death, most likely related to the reduc-
tion in bleeding complications.
The present data suggest that heparin mono-
therapy is sufﬁcient for most patients who undergo
PCI with radial access. Patients at high risk for
ischemic complications or stent thrombosis (bifurca-
tion or long lesions, among others) may be treated
with unfractionated heparin with newer P2Y12 an-
tagonists. In contrast, patients with a higher risk for
bleeding (older women presenting with ACS and
where femoral access is used for the intervention)
may beneﬁt from bivalirudin.
ACCESS AND BLEEDING COMPLICATIONS
FEMORAL ARTERY ACCESS. Access-site bleeding
complications predominate, especially in the setting
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measures and strategies known to lower bleeding
rates from access sites. The femoral artery has tradi-
tionally been used for PCI in the United States, and
approximately 80% of PCIs are performed through
this route (63,64). It also is a preferred route for
procedures that require larger catheters. For ex-
ample, operators still prefer the femoral access route
for distal left main, complex bifurcation lesions, and
rotational atherectomy with large burrs. Trans-
catheter aortic valve replacements and other periph-
eral vascular procedures are also performed through
femoral or apical routes due to the need for large
catheters.
Few studies have looked into the advantages of
using smaller-size sheaths, ﬂuoroscopy, and intra-
vascular ultrasound for femoral artery access (65).
The data are derived from a single center (17), but
observations from randomized trials and registries
are consistent and support the use of a micropuncture
needle (FEMORIS [Femoral Micropuncture or Routine
Introducer Study]; 21-gauge vs. 18-gauge needle) (66);
ﬂuoroscopy or ultrasound (FAUST [Femoral Arterial
Access With Ultrasound Trial]) (67) to target the
common femoral artery; smaller sheath size; and
early sheath removal. On the basis of these observa-
tions, operators are encouraged to use ﬂuoroscopy
and micropuncture needles with ultrasound guid-
ance, with the goal of performing safe zone arteri-
otomy (access between the inferior epigastric artery
above and the bifurcation of the common femoral
artery below).
RADIAL ARTERY ACCESS. Radial artery access has
consistently demonstrated reduction in bleeding and
vascular complications following PCI compared with
femoral artery access in observational registries and
randomized trials (63,68,69). In the randomized trial,
RIVAL (Radial Vs Femoral Access for Coronary Inter-
vention), the primary outcome of death, myocardial
infarction, stroke, or non-CABG–related bleeding at
30 days occurred in 3.7% in the radial access group,
which was not different from the 4.0% observed in
patients randomized to femoral access (70). However,
if the deﬁnition of bleeding was broadened to include
large hematomas and pseudoaneurysms, signiﬁcant
differences favoring radial access were observed be-
tween the 2 groups. In the recently-published MA-
TRIX trial, 8,404 patients with ACS were randomized
to radial (n ¼ 4,197) or femoral (n ¼ 4,207) access for
coronary angiography and PCI. Major adverse car-
diovascular events were noted in 8.8% of patients
with radial access, compared with 10.3% of patients
with femoral access. The net adverse clinical events,
including bleeding events, favored patients in theradial access group: 410 (9.8%) patients with radial
access had net adverse clinical events compared with
486 (11.7%) patients with femoral access. The differ-
ence was driven by BARC major bleeding unrelated to
CABG surgery (1.6% vs. 2.3%) and all-cause mortality
(1.6% vs. 2.2%) (71). The largest observational NCDR
also demonstrated that radial access was associated
with a signiﬁcant reduction in bleeding and vascular
complications (14,62). The most signiﬁcant reduction
in bleeding rates was observed in patients with STEMI
treated via radial access. Patients with STEMI repre-
sent the highest risk for both ischemic and bleeding
complications. In some randomized trials and meta-
analyses, use of the radial approach for access in
primary angioplasty resulted in reduced mortality
(69,70,72). With heterogeneity in trial inclusion
criteria and with the majority of deaths in patients
without a major bleed, there is a lack of a distinct,
mechanistic link between mortality reduction and
radial access that was observed in some studies (34).
However, these results underscore the need to use
radial access in this subgroup, which is the most
prone to bleeding complications following PCI.
In addition to lowering bleeding complications,
radial access has cost advantages, promotes early
ambulation and discharge, and is preferred by pa-
tients (1,70,73). However, despite these advantages,
there is a distinct learning curve for proﬁciency in
using radial artery access for cardiac catheterization
and PCI. In a pre-speciﬁed subgroup analyses from
the RIVAL trial, the primary outcome was reduced
(hazard ratio: 0.49, 95% conﬁdence interval: 0.28 to
0.87) in high-volume radial centers, deﬁned as the
operator’s annual median radial PCI volume >146
(74). Clinical data from 1,298 facilities reporting to the
NCDR show that 49% of facilities in the United States
performed #400 PCIs and 26% performed #200 PCIs
annually; hence, replicating these results in lower-
volume centers may be challenging (75). Procedural
learning, however, continues, with further improve-
ment noted in dedicated radial PCI operators who
switch from transfemoral angiography (76). In a
recent study from the NCDR, higher-risk patients
were chosen for transradial PCI with increased
operator radial PCI volume (77). Despite this, oper-
ator proﬁciency improved, and the threshold for
overcoming the learning curve appeared to be
approximately 30 to 50 cases. There is growing pub-
lished data on the learning curve for transradial PCIs,
and despite study differences, 25 to 80 cases are
needed for novice operators (78). In summary,
volume-outcome relationships are evident in learning
transradial PCIs, and available data support higher-
volume radial PCI centers to improve PCI outcomes.
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sion is a distinct complication of radial access, and its
incidence ranges from 2% to 10% following trans-
radial access (79). To prevent ischemia and reuse the
same site for bypass conduit or cardiac catheteriza-
tion, the Society for Cardiovascular Angiography and
Interventions radial committee recently recom-
mended a standardized anticoagulation protocol, us-
ing the lowest-proﬁle sheaths, patent hemostasis
(80), or radial compression guided by mean artery
pressure techniques (81) to reduce its incidence
(82). Similar recommendations were made to reduce
radiation exposure and to transition to perform pri-
mary PCI.
The RADAR (Predictive Value of Allen’s Test Result
in Elective Patients Undergoing Coronary Catheteri-
zation Through Radial Approach) trial (83) did not
ﬁnd a relationship between functional assessment of
dual-artery circulation to the hand by the Allen test
and plethysmography and measures of distal
ischemia, collaterals between the radial and ulnar
arteries, and functionality of the hand following
radial access. The Allen test was abnormal in 30% and
a D pattern by plethysmography was detected in 40%
of 942 screened patients. The investigators suggested
the feasibility of transradial access across the spec-
trum of Allen test results. Further studies are needed
to test this proof-of-concept.
VCDs AND BLEEDING COMPLICATIONS. VCDs have
been demonstrated to reduce time to ambulation and
increase patient comfort (84–86). Recent observa-
tional registries and subgroup analyses from ran-
domized trials have noted reductions in the incidence
of bleeding complications with VCDs following inva-
sive femoral angiography or PCI; however, there is a
lack of randomized trial data to support their use for
these indications (87–89). Observational registry data
from NCDR and Blue Cross Blue Shield of Michigan
demonstrated lower bleeding risk with VCD use
(8,90,91). However, meta-analyses and randomized
trials comparing bleeding rates following manual
compression or from VCD failed to show lower
bleeding rates with VCD (84,88,92). To accurately
portray the role of VCDs, a high-quality, adequately-
powered randomized trial needs to be performed with
intention-to-treat and concealment of allocation of
manual versus VCD strategy. We also need to account
for the learning curve and do post-marketing sur-
veillance to monitor device complications (93,94).
Not only is the use of VCDs associated with compli-
cations unique to device deployment (loss of limb
circulation or severe infection) (95), but also device
failure (1.5% to 20%) is associated with signiﬁcantlyhigher bleeding complications (96). Gurm et al. (90)
noted, in a large observational registry, a reduction
in hematoma and pseudoaneurysm, but also a sig-
niﬁcant increase in retroperitoneal bleeds with the
use of VCDs. Their usefulness to reduce bleeding and
vascular complications was attenuated in patients
with low BMI and in those on GP IIb/IIIa agents (90).
In a recent study from the Massachusetts Department
of Health, VCD failed in 3.3% of 23,813 procedures
(97). VCD failure was associated with excess risk of
any (7.7% vs. 2.8%) or major (3.3% vs. 0.8%) vascular
complications, as compared with successful VCD
deployment, underscoring the need for physicians to
be vigilant of predictors of VCD failure (female sex,
peripheral vascular disease, and emergency status).
These are the same variables that increase the risk of
bleeding, and their cautious use or avoidance would
be recommended until additional data are accrued.
ADOPTION OF BEST PRACTICES TO
LOWER BLEEDING COMPLICATIONS
Recent analyses of a nationally-representative U.S.
PCI population suggest that 12.1% of all in-hospital
mortality after PCI may be related to bleeding com-
plications, and may therefore be modiﬁable, and that
the number needed to harm (NNH) calculations sug-
gest that the mortality risk associated with bleeding
was greatest in patients at the highest bleeding risk
(NNH ¼ 21) or with nonaccess-site bleeding (NNH ¼
16) (5). Likewise, the NNH was lowest in patients age
75 years or older and in patients with STEMI or low
glomerular ﬁltration rate. These high-risk subgroups
may have the greatest potential for mortality reduc-
tion through bleeding avoidance and should be pref-
erentially targeted.
Individualizing and stratifying bleeding risk before
coronary angiography and intervention is paramount
(Central Illustration). Not only can one tailor the
choice of vascular access, but modiﬁcation of anti-
coagulation strategies by pre-treatment with dual
antiplatelet therapy and use of bivalirudin to lower
access- and nonaccess-site bleeds in patients deemed
to be higher risk will likely lower their bleeding
complications. Excessive bleeding is also associated
with acute kidney injury and ischemic complications;
thus, preventing bleeding complications will trans-
late into overall improvement in PCI outcomes (98).
Recognition and mitigation of bleeding risk
following PCI is a recognized health care priority.
Despite consistent observations from contemporary
registry data documenting reductions in vascular and
bleeding complications, there is still a paucity of
systematic efforts to lower bleeding in these patients.
CENTRAL ILLUSTRATION Bleeding Complications Following
PCI: Proposed Processes Designed To Lower Bleeding
Complications Following PCIs
•  Participation in NCDR CATH-PCI Registry
•  Periodic assessment of bleeding avoidance 
strategies (BAS)
•  Monitor ischemic and bleeding
complications
•  Track complications unique to access
(VCD or radial artery occlusion)
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•  Routine use of bleeding risk tool
•  Pretreatment with Dual Antiplatelet Therapy 
(DAPT) if appropriate
•  Use radial access as default strategy
•  Aim for lower activated clotting time (ACT) levels: 
- 200-250 secs with GPIIb/IIIa inhibitors
- 250-300 secs with/without GPIIb/IIIa inhibitors
•  Use of Bivalirudin for high-risk cases
(more data needed)
•  Judicious and selective use of GPIIb/IIIa inhibitors
•  Fluoroscopy, ultrasound, and micropuncture-guided 
femoral access
•  Early sheath removal
•  Vascular closure device (VCD) for early ambulation 
(more data needed to demonstrate efficacy to lower 
bleeding complications)
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Singh, M. J Am Coll Cardiol. 2015; 65(20):2225–38. 
ACT ¼ activated clotting time; BAS ¼ bleeding avoidance strategies; DAPT ¼
dual antiplatelet therapy; GP ¼ glycoprotein; NCDR ¼ National Cardiovas-
cular Data Registry; PCI ¼ percutaneous coronary intervention; VCD ¼
vascular closure device.
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2234Marso et al. (8) used the available risk model to
categorize patients in a large population undergoing
PCI into different tertiles of bleeding risk. In that
study, the use of VCD and bivalirudin lowered
bleeding rates, especially among patients at the
greatest risk for bleeding. The strategies that lowered
bleeding risk were used less commonly in the sub-
group with the highest bleeding risk (risk-treatment
paradox). In another study, incorporation of individ-
ualized risk estimates in the consent form led to
reversal of this paradox through rational increase in
the use of bivalirudin (23). At the Mayo Clinic, pre-
treatment with dual antiplatelet agents has reduced
the need for GP IIb/IIIa agents, and a concomitant
increase in the adoption of radial access for PCI hasresulted in reduction of bleeding and vascular com-
plications (unpublished data). Reduction of bleeding
complications with the use of bivalirudin needs to be
put in perspective. Recent data from HEAT-PPCI and
now from the BRIGHT and MATRIX trials comparing
bivalirudin versus heparin has rekindled the debate
on anticoagulation during PCI. It has encouraged the
use of heparin monotherapy with pre-loading of dual
antiplatelet therapy. Bivalirudin has demonstrated
lowered bleeding and may be advantageous in pa-
tients with a high likelihood of bleeding. Unlike
HEAT-PPCI, the BRIGHT and MATRIX trials reported
lower bleeding; hence; there is a need to revisit the
value proposition of bivalirudin. For example, older
patients, women, those with renal dysfunction, and
those presenting with ACS are subgroups that will
beneﬁt preferentially from bleeding avoidance stra-
tegies, including radial access and bivalirudin. More
studies need to be performed to lower the acute
thrombotic risk with bivalirudin, and readers are
encouraged to read the recent meta-analysis on this
topic (58). If ischemic complications in the ﬁrst 24 h
following bivalirudin administration can be lowered,
short- and long-term prognoses seem excellent (99).
In the Swedish Coronary Angiography and Angio-
plasty Registry, an additional bolus dose of unfrac-
tionated heparin was associated with a lower rate of
death or deﬁnite target lesion thrombosis at 30 days
in patients undergoing primary PCI with bivalirudin
as the anticoagulant (60). The BRIGHT trial demon-
strated the usefulness of prolonged bivalirudin infu-
sion in lowering ischemic events among patients with
acute myocardial infarction undergoing emergent PCI
(61).
The recent observational data on the use of VCD to
lower bleeding rates following PCI is encouraging
(87,89,90). However, the results of meta-analyses of
randomized trials are not concordant. At present, the
use of VCD to lower bleeding and vascular complica-
tions cannot be recommended, and there is a need for
an adequately-powered randomized trial.
The use of the radial artery for access has
increased, albeit at a slower pace in North America.
Most trials, including the recent MATRIX trial, and
registry data support the use of the radial artery to
lower access-site bleeding complications. Substantial
expertise is needed to perform PCI through the radial
approach, and the best outcomes have only been re-
ported at high-volume centers. The prognostic link
between bleeding and survival prompts consider-
ation of radial artery access as a default strategy in
most patients, but especially in patients who are at
high bleeding risk (older patients presenting with
ACS), who will derive the most beneﬁt from this
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2235change (100). In a large study from the British Car-
diovascular Intervention Society database, a 35%
reduction in 30-day mortality with radial artery ac-
cess for PCI was seen across various risk categories,
but was most evident in patients at the highest
baseline bleeding risk (4). Current efforts to train
interventional fellows and consultants will certainly
increase adoption of this technique, but at the same
time, the role and safety of femoral access should not
be undermined. Readers are encouraged to review
the meta-analysis comparing radial and femoral ac-
cess for coronary angiography and interventions
(70,101). Femoral access is still needed for larger
sheath sizes, complex left main interventions, rota-
tional atherectomy with large burrs, transaortic valve
replacement (TAVR), intra-aortic balloon pump and
other assist devices, and abdominal and lower-
extremity angiography and interventions. High rates
of bleeding complications are noted in patients
undergoing TAVR. A recent study demonstrated a
reduction in major bleeding rates with the adoption
of heparin doses according to the ACT value. Major
bleeding was higher in patients treated with a
weight-based dosing strategy (33.5% vs. 7.5%,
p < 0.001). Multivariate adjustment favored the use
of ACT-based dosing of heparin, with a signiﬁcantly
lower incidence of 30-day major bleeding (102).
Recently, the use of the radial crossover technique,
with a salutary effect on bleeding, has been described
for tortuous contralateral femoral arteries in patients
undergoing TAVR (103).
The data on angiograms and PCI in patients with
prior bypass surgery also favor the transfemoral route
(104). More data are needed to support the routine
use of ﬂuoroscopy, micropuncture needle withultrasound assistance, smaller sheath size, early
sheath removal, and use of the right dose of anti-
coagulation agents that will likely lower bleeding
and vascular complication rates from femoral access.
We eagerly await the results of SAFARI-STEMI
(Femoral Versus Radial Access for Primary PCI;
NCT01398254) (105).
SUMMARY AND CONCLUSIONS
New iterations of catheters, closure devices, and
anticoagulation doses and regimens have lowered
bleeding rates following PCI; however, bleeding still
accounts for signiﬁcant morbidity and mortality.
Tools to estimate an individual’s bleeding risk need
to be routinely used. The bleeding risk is modiﬁ-
able; therefore, interventionalists are encouraged to
adopt the safest and best practices to lower the
bleeding rates. Operators need to choose the right
anticoagulation agent and administer the right dose.
Switching to radial access for PCI will be a paradigm
shift for operators who have previously used
femoral access. It has a learning curve, and only
high-volume operators will be able to demonstrate
lower bleeding rates and improved outcomes. Pro-
ﬁciency in femoral access is still required. Adoption
of best practices to lower bleeding rates will
certainly improve quality of care and downstream
outcomes of PCI.
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